As an investor in Neuren since 2013 I am doing pretty well. It has been a long but overall exciting ride.
My main interest now is the combined results of the upcoming three 2591 P2 trials.
If overall success is achieved that will be good enough for me and the end of concentration on profit. My over-riding hope is that thereafter 2591 would progess along a pathway which maximises medical benefit over profit, whatever that pathway may be.
Brickbats to those who have ridiculed the idea that investing is purely about maximising the almighty dollar. We are not all the same in that respect.
- Forums
- ASX - By Stock
- NEU
- Ann: 2023 Results webinar
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.54%
!
$12.92

Ann: 2023 Results webinar, page-121
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.92 |
Change
0.070(0.54%) |
Mkt cap ! $1.617B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.85 | $8.049M | 616.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4175 | $12.91 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.03 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4175 | 12.910 |
5 | 6250 | 12.900 |
2 | 1762 | 12.890 |
2 | 3348 | 12.880 |
1 | 1508 | 12.850 |
Price($) | Vol. | No. |
---|---|---|
12.940 | 5030 | 2 |
12.950 | 2088 | 2 |
12.960 | 514 | 1 |
12.970 | 1862 | 2 |
12.980 | 5442 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online